Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females aged 18 years or older with histologic or cytologic diagnosis of adenocarcinoma originating in the breast~* Radiologic or pathologic evidence that the cancer is metastatic or locally advanced (a T4 tumor and stage IIIB/IIIC disease) and not curable by local measures, such as radiation or surgery~* Positive status for human epidermal growth factor receptor 2~* Measurable disease as per Response Evaluation Criteria In Solid Tumors guidelines~* Karnofsky performance status of 70 to 100~* Life expectancy of at least 3 months~Exclusion Criteria:~* Prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine~* Common Terminology Criteria Grade 2 or greater neuropathy~* Inadequate hematologic, hepatic, or renal function~* Known prior severe hypersensitivity reactions to agents containing Cremophor® EL or known hypersensitivity or prior intolerance to fluoropyrimidine~* Known or suspected dihydropyrimidine dehydrogenase deficiency~* More than 3 prior chemotherapy regimens in the metastatic setting~* Prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg (Type: EXPERIMENTAL): Dose Level 1
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg (Type: EXPERIMENTAL): Dose Level 2
- Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg (Type: EXPERIMENTAL): Dose Level 3
- Ixabepilone + Lapatinib + Capecitabine (Type: EXPERIMENTAL): Triplet Combination

Based on this trial design, predict the completion outcome and termination type (if applicable).